Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The ongoing advancements in cancer treatment are continuously reshaping patient care, particularly in hematological malignancies like Acute Myeloid Leukemia (AML). For individuals with intermediate-to-low-risk AML, the focus has shifted towards strategies that ensure long-term health and prevent disease recurrence. NINGBO INNO PHARMCHEM CO.,LTD. contributes to these innovations by providing high-quality pharmaceutical intermediates essential for the synthesis of novel AML therapies.
A significant development in AML management is the increasing evidence supporting the efficacy of maintenance therapy. Studies examining patients with intermediate risk AML have shown that combining Venetoclax (VEN) with Azacitidine (AZA) as a maintenance regimen significantly reduces the likelihood of relapse. This advancement is crucial for improving progression-free survival (PFS) and offering patients a more durable remission.
The potential of VEN-AZA therapy is also being explored for patients with low risk AML, aiming to enhance remission depth and prevent disease re-emergence. The strategy is to build upon the success of initial treatments and provide sustained control over the leukemia.
A thorough understanding of the venetoclax azacitidine adverse events is critical for safe and effective treatment. NINGBO INNO PHARMCHEM CO.,LTD. ensures that the pharmaceutical intermediates supplied meet stringent quality and purity standards, which is vital for the safety and efficacy of the final medicinal products. Managing potential side effects is an ongoing aspect of clinical practice.
The achievement of MRD (Minimal Residual Disease) negativity is a key goal in AML treatment, as it is strongly associated with better long-term outcomes. Therapies involving VEN-AZA are showing promise in facilitating and maintaining this deep level of remission. NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting the pharmaceutical sector in its efforts to develop and deliver these life-improving treatments for AML patients.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
